Recently, CAR-T has emerged as a significant advancement in the management of hematological tumors, particularly B-cell malignancies, mainly due to the presence of specific antigens such as CD19 and BCMA. Here, CD19 is linked to hematopoietic and lymphoid system neoplasm.